CMRA (Comera Life Sciences Holdings) Total Inventories: $0.00 Mil (As of Sep. 2023)


What is Comera Life Sciences Holdings Total Inventories?

Comera Life Sciences Holdings CMRA Total Inventories is $0.00 Mil as of Sep. 2023.

Comera Life Sciences Holdings's total inventories for the quarter that ended in Sep. 2023 was $0.00 Mil. Comera Life Sciences Holdings's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Sep. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Comera Life Sciences Holdings's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was $-0.18.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Comera Life Sciences Holdings's Days Inventory for the three months ended in Sep. 2023 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Comera Life Sciences Holdings's Inventory-to-Revenue for the quarter that ended in Sep. 2023 was 0.00.

Comera Life Sciences Holdings  (OTCPK:CMRA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Comera Life Sciences Holdings's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is

Net-Net Working Capital Per Share (Q: Sep. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.768+0.75 * 0+0.5 * 0-7.293
-0-0)/30.738
=-0.18

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Comera Life Sciences Holdings's Days Inventory for the three months ended in Sep. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2023 )/Cost of Goods Sold (Q: Sep. 2023 )*Days in Period
=0/0.042*365 / 4
=0.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Comera Life Sciences Holdings's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2023 ) / Average Total Inventories (Q: Sep. 2023 )
=0.042 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Comera Life Sciences Holdings's Inventory to Revenue for the quarter that ended in Sep. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=0 / 0.136
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Comera Life Sciences Holdings Total Inventories Related Terms

Comera Life Sciences Holdings Total Inventories Historical Data

* Premium members only.

The historical data trend for Comera Life Sciences Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Comera Life Sciences Holdings Total Inventories Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
Total Inventories
0.00 0.00 0.00

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Comera Life Sciences Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.00 Mil mean?
Comera Life Sciences Holdings (CMRA) has a Total Inventories of $0.00 Mil as of Sep. 2023. The total amount of inventory as recorded on a company's balance sheet. View historical data for Comera Life Sciences Holdings and its competitors.
Is Comera Life Sciences Holdings' Total Inventories too high?
Comera Life Sciences Holdings' current Total Inventories is $0.00 Mil.
How does Comera Life Sciences Holdings' Total Inventories compare to FREQ and BNTC?
Comera Life Sciences Holdings' Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Comera Life Sciences Holdings and its competitors. Comera Life Sciences Holdings's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Comera Life Sciences Holdings stock overvalued right now?
Comera Life Sciences Holdings (CMRA) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Comera Life Sciences Holdings (CMRA), the current Total Inventories is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Comera Life Sciences Holdings Business Description

Address 12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.